BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29205803)

  • 1. Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience.
    Asil S; Kaya B; Canpolat U; Yorgun H; Şahiner L; Çöteli C; Arat A; Aytemir K
    Catheter Cardiovasc Interv; 2018 Sep; 92(3):557-565. PubMed ID: 29205803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.
    Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S
    J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Veselka J; Honek T
    Int J Cardiol; 2003 Mar; 88(1):27-32. PubMed ID: 12659981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy.
    Shelke AB; Menon R; Kapadiya A; Yalagudri S; Saggu D; Nair S; Narasimhan C
    Indian Heart J; 2016; 68(5):618-623. PubMed ID: 27773399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients.
    Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T
    Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy.
    Liu L; Li J; Zuo L; Zhang J; Zhou M; Xu B; Hahn RT; Leon MB; Hsi DH; Ge J; Zhou X; Zhang J; Ge S; Xiong L
    J Am Coll Cardiol; 2018 Oct; 72(16):1898-1909. PubMed ID: 30309466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
    Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
    Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of coil embolization of the septal perforator for septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Guerrero I; Dhoble A; Fasulo M; Denktas AE; Sami S; Choi S; Balan P; Arain SA; Smalling RW
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):971-977. PubMed ID: 27511120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes.
    Gross CM; Schulz-Menger J; Krämer J; Siegel I; Pilz B; Waigand J; Friedrich MG; Uhlich F; Dietz R
    J Endovasc Ther; 2004 Dec; 11(6):705-11. PubMed ID: 15615561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of transthoracic echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation for the treatment of patients with obstructive hypertrophic cardiomyopathy].
    Liu LW; Zuo L; Zhou MY; Li J; Zhou XD; He GB; Zhang J; Zhang JZ; Liu B; Yang J; Xu B
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Apr; 47(4):284-290. PubMed ID: 31060187
    [No Abstract]   [Full Text] [Related]  

  • 11. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy through non-left anterior descending septal perforators.
    Imori Y; Takano H; Kitamura M; Aoyama R; Sangen H; Kenta O; Matsuda J; Kubota Y; Tokita Y; Yamamoto T; Asai K; Takayama M; Shimizu W
    Heart Vessels; 2020 May; 35(5):647-654. PubMed ID: 31641886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up.
    Durand E; Mousseaux E; Coste P; Pillière R; Dubourg O; Trinquart L; Chatellier G; Hagège A; Desnos M; Lafont A
    Eur Heart J; 2008 Feb; 29(3):348-55. PubMed ID: 18203702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results.
    Oomman A; Ramachandran P; Subramanyan K; Kalarickal MS; Osman MN
    J Invasive Cardiol; 2001 Jul; 13(7):526-30. PubMed ID: 11435640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy and safety of coil embolization of septal branch in the treatment of patients with obstructive hypertrophic cardiomyopathy].
    Liu H; Wu Q; Tan HW; Pang J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1044-1048. PubMed ID: 29325364
    [No Abstract]   [Full Text] [Related]  

  • 15. Percutaneous alcohol septal ablation for hypertrophic obstructive cardiomyopathy: technical review and long-term clinical and echocardiographic outcomes.
    Leal S; Galeote G; Jiménez-Valero S; Sánchez-Recalde A; Salinas P; Ruiz AS; Orbe LC; Dominguéz F; Moreno R; López-Sendón JL
    Rev Port Cardiol; 2012 May; 31(5):363-71. PubMed ID: 22482474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy.
    Seggewiss H; Faber L; Gleichmann U
    Thorac Cardiovasc Surg; 1999 Apr; 47(2):94-100. PubMed ID: 10363608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Looking back on 15 years of ultrasound-guided alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
    Vermaete I; Dujardin K; Stammen F
    Acta Cardiol; 2020 Oct; 75(6):483-491. PubMed ID: 31204591
    [No Abstract]   [Full Text] [Related]  

  • 18. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
    Nagueh SF; Lakkis NM; Middleton KJ; Killip D; Zoghbi WA; Quiñones MA; Spencer WH
    J Am Coll Cardiol; 1999 Oct; 34(4):1123-8. PubMed ID: 10520801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conduction Disturbances and Arrhythmia Risk After Septal Reduction Therapy with Alternative Agents: A Pilot Study with EVOH-DMSO and Systematic Review.
    Asil S; Aytemir K
    Turk Kardiyol Dern Ars; 2023 Jan; 51(1):40-49. PubMed ID: 36689282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography].
    Faber L; Seggewiss H; Fassbender D; Bogunovic N; Strick S; Schmidt HK; Gleichmann U
    Z Kardiol; 1998 Mar; 87(3):191-201. PubMed ID: 9586154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.